Floatz logo

USISTAPIDE

Nutritional and Metabolic Diseases

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Nutritional and Metabolic Diseases cohort.

Asset / SponsorPhaseRating
Liraglutide
Anders Fink-Jensen, MD, DMSci
Phase 4A
Semaglutide
Nordsjaellands Hospital
Phase 4A
Metformin
Jinnah Sindh Medical University
Phase 4BBB
Tirzepatide
Washington University School of Medicine
Phase 4BBB
PRAVASTATIN
National Human Genome Research Institute (NHGRI)
Phase 4BBB

View all 50 →

Same molecule, other indications

USISTAPIDE is also rated in:

nutritional deficiency diseaseDormant
B
Indicative ·
62 / 100
View asset →
type 2 diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →
diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →